Mode
Text Size
Log in / Sign up
Phase 3 N=49 Randomized Single-blind Treatment

Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts

Tobacco Use Cessation

Enrolled (actual)
49
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Adherence to NRT — 47.4; 32.7 days of NRT use

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Nicoderm CQ 21Mg/24Hr Transdermal System (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Brown University
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Adherence to NRT
47.4; 32.7
SECONDARY
7 Day Point Prevalence Abstinence
4; 4

Summary

The overall goal of this research project is to examine the feasibility, acceptability, and preliminary efficacy of nicotine replacement therapy preloading (NRT-P) in HIV-positive smokers, who are struggling with cigarette dependence, urge to smoke (craving) and low self-efficacy as barriers to successful smoking cessation. Sixty participants will be recruited into a 16-week randomized pilot study. Thirty participants (control condition) will receive standard smoking cessation counseling (NRT-S) and will initiate an 8-week course of combination nicotine patch and lozenge (or gum, based on preference) on quit date (week 4), consistent with recommended guidelines based on smoking rate. Thirty participants (active condition) will start NRT patch 3 weeks prior to quit date, followed by an 8-week course of combination nicotine patch and lozenge (or gum, based on preference), initiated on quit date. The investigators will examine dependence, urge to smoke and self-efficacy for quitting prior to and following quit date. The investigators will also examine differences in quit attempts and biochemically validated smoking abstinence between the control and active conditions at weeks 8, 12, and 16.

Eligibility Criteria

Inclusion Criteria

  • diagnosed with HIV
  • at least 18 years of age
  • smoking at least 5 cigarettes/day
  • exhaled Carbon Monoxide level greater than 5 at baseline
  • willing to use transdermal nicotine patch
  • ready to quit in the next 30 days.

Exclusion Criteria

  • currently using pharmacotherapy for smoking cessation
  • medically or psychiatrically unstable (defined as: uncontrolled hypertension, unstable angina, or a medical or psychiatric hospitalization in the 30 days prior to enrollment) *experiencing psychotic symptoms
  • endorsing suicidal ideation upon screening or past-year suicide attempt
  • pregnant or nursing.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04994444). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search